Preclinical studies showed that ICEC0942 inhibits proliferation in numerous cancer cell types in vitro but also demonstrated that ER-positive cells were especially susceptible to ICEC0942 as a single agent or in combination with endocrine therapies, providing a rationale for the use of CDK7 inhibitors in the treatment of ER-positive breast cancer [65]. Here, CDK7 is linked to cancer.